MSK has focused on studying central nervous system (CNS) lymphoma for more than 40 years. We are a leader in developing clinical trials for treating this disease.
In the laboratory, we are conducting research to find new treatments for CNS lymphoma. We have collected almost 200 tumor samples and conducted genetic analysis on them. These samples are anonymously linked to clinical data. This helps us make connections between specific genetic changes and the response to particular drugs or overall outcomes.
We are also using these samples to develop models for studying the disease in the lab and to look for new drugs that can be tested in clinical trials. Our research has already revealed information about the changes in cells that cause CNS lymphoma and suggested ways to target those changes.
Learn more about the clinical trials we are currently conducting: